Use of Reference Change Value for Dyslipidemia Follow up

Dikker, Okan; SAHIN, MUSTAFA

Use of Reference Change Value for Dyslipidemia Follow up

Okan DİKKER, (Department of Medical Biochemistry, University of Health Sciences, Okmeydanı Education and Research Hospital, Istanbul, Turkey)

Mustafa ŞAHİN (Department of Medical Biochemistry, Hitit University, Erol Olcok Education and Research Hospital, Corum, Turkey)

Türk Klinik Biyokimya Dergisi

0 0

Yıl: 2019 Cilt: 17 Sayı: 2 Sayfa Aralığı: 63 - 69 Metin Dili: İngilizce İndeks Tarihi: 04-06-2020

Use of Reference Change Value for Dyslipidemia Follow up

Öz:

Aim: Lipid profile is used to determine the risk of cardiovascular diseases (CVD) and to monitor treatment. Reference change value (RCV) represents the clinical significance of the variation between the results of two consecutive tests and laboratory test results exceeding this value are associated with the individual’s disease status. In our study, we aimed to calculate the RCV for lipid profile tests such as total cholesterol, triglyceride, HDL-cholesterol and LDL-cholesterol, additionally, to assess the clinical use of the RCV in order to determine to the risk of CVD and monitoring their treatment. Materials and Methods: The analytic coefficient of variation (CVA) was calculated from internal quality control results. The intra-individual coefficient of variation (CVI) and inter-individual coefficient of variation (CVG) were obtained from Westgard’s website. For each test, the index of individuality (II) was calculated with the CVI/CVG ratio. To assess tests with index of individuality below 1, percentage of the RCV (RCV%) was used. The RCV% is calculated with the formula z.21/2.[CVA2+CVI2] 1/2. Results: The RCV% results were calculated as 15% for total cholesterol, 47% for triglyceride, and 19% for HDL-cholesterol and LDL-cholesterol. The II was calculated as 0.388 for total cholesterol, 0.608 for triglyceride, 0.344 for HDL-cholesterol and 0.382 for LDL-cholesterol. Conclusion: The results for RCV% values identified for lipid profile in the literature are similar to the results obtained in our study. In clinical practice, when the difference between two consecutive lipid profile tests exceed the RCV%, it should be interpreted as a significant change. The RCV% may be used to assess the CVD risk and the efficacy of dyslipidemia treatment.

Anahtar Kelime:

Dislipidemi Takibinde Referans Değişim Değerinin Kullanımı

Öz:

Amaç: Kardiyovasküler hastalıklar (KVH) için risk belirlemede ve tedavi takibinde lipit profilinden yararlanılır. Referans değişim değeri (RCV), ardışık iki test sonucu arasındaki değişikliğin klinik önemini ifade eder ve bu değeri aşan laboratuvar test sonuçları bireyin hastalık durumu ile ilişkilidir. Çalışmamızda total kolesterol, trigliserit, HDL-kolesterol ve LDL-kolesterol gibi lipit profili testlerine ait referans değişim değerini (RCV) hesaplamayı ve kardiyovasküler hastalıklar için risk belirleme ve tedavi takibinde RCV'nin klinik kullanımını değerlendirmeyi amaçladık. Gereç ve Yöntem: İç kalite kontrol sonuçlarından analitik varyasyon katsayısı (CVA) hesaplandı. Birey içi varyasyon katsayısı (CVI) ve bireyler arası varyasyon katsayısı (CVG) değerleri Westgard’ın web sitesinden elde edildi. Herbir test için bireysellik indeksi (BI), CVI/CVG oranı ile hesaplandı. BI değeri 1’in altında olan testlerin değerlendirilmesinde %RCV esas alındı. Elde edilen verilerle %RCV=(z.21/2.[CVA2+CVI2] 1/2) formülü ile hesaplandı. Bulgular: %RCV sonuçları; total kolesterol için %15, trigliserit için %47, HDL-kolesterol ve LDLkolesterol için %19 olarak hesaplandı. BI; kolesterol için 0,388, trigliserit için 0,608, HDL-kolesterol için 0,344 ve LDL-kolesterol için 0,382 olarak hesaplandı. Sonuç: Literatürde lipid profili için belirtilen % RCV değerleri, çalışmamızda elde edilen sonuçlara benzerdir. Klinik pratikte, iki lipit profili test sonucu arasındaki fark %RCV’yi aştığı zaman anlamlı bir değişiklik olarak yorumlanmalıdır. KVH riski ve dislipidemi tedavisi etkinliğini değerlendirmede %RCV kullanışlı olabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ricós C, Arbós MA. Quality goals for hormone testing. Ann Clin Biochem. 1990; 27:353-8.
2. Fraser FG. The nature of BV. In: Fraser CG. Biological variation: from principles to practice. Washington: AACC Press Washington, 2001:1-28.
3. Fraser CG. Changes in serial results. In: Biological variation: from principles to practice. Washington: AACC Press, 2001:67-90.
4. Ozturk OG, Paydas S, Balal M, Sahin G, Karacor ED, Ariyurek SY et al. Biological variations of some analytes in renal posttransplant patients: A different way to assess routine parameters. J Clin Lab Anal 2013; 27: 438-43.
5. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart Disease and Stroke Statistics—2013 Update A Report From the American Heart Association. Circulation 2013;127: e6–e245.
6. Türkiye Endokrinoloji ve Metabolizma Derneği, Dislipidemi Tanı ve Tedavi kılavuzu 2018- http://www.temd.org.tr/admin/uploads/tbl_gruplar/2 0180525144116-2018-05- 25tbl_gruplar144111.pdf
7. Westgard JO, Groth T. Design and evaluation of statistical control procedures: Applications of a computer "quality control simulator" program. Clin Chem 1981; 27: 1536-45.
8. https://www.westgard.com/biodatabase1.htm (erişim tarihi: 31.10.2018)
9. Fraser CG. Inherent biological variation and reference values. Clin Chem Lab Med 2004; 42: 758-64.
10. Biosca C, Ricós C, Lauzurica R, Galimany R, Hyltoft Petersen P. Reference change value concept combining two delta values to predict crises in renal post-transplantation. Clin Chem. 2001; 47:2146-8.
11. World Health Organization. Cardiovascular diseases (CVDs). Available from URL: http:// www.who.int/ mediacentre/ factsheets/fs317/en/inex.html
12. Murray CJL, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study Lancet 1997; 349: 1498- 1504.
13. Emberson JR, Whincup PH, Morris RW Walker M. Reassessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. European Heart Journal 2003; 24: 1719–26.
14. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of choleste-rol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005; 21: 1389-99.
15. S.F. Benozzi, G. Unger, A. Campion, G.L. Pennacchiotti, Fasting conditions: influence of water intake on clinical chemistry analytes, Biochem Med (Zagreb) 28 (2018) 1–8.
16. Šupak-Smolčić V, Antoncic D, Ozanić D, Vladilo I, Bilic-Zulle L. Influence of a prolonged fasting and mild activity on routine laboratory tests. Clin Biochem. 2015;48:85–8.
17. Nunes LA, Brenzikofer R, de Macedo DV. Reference change values of blood analytes from physically active subjects. Eur J Appl Physiol. 2010;110:191- 198.
18. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989; 27:409-37.
19. Training AN. Biological Variation and Reference Change Value (Rcv) of Prostate Specific Antigen ( Psa) Levels in the Serum of. 2009;152–6.
20. Garner AE, Lewington AJ, Barth JH. Detection of patients with acute kidney injury by the clinical laboratory using rises in serum creatinine: Comparison of proposed definitions and a laboratory delta check. Ann Clin Biochem 2012; 49: 59-62.
21. Iglesias N, Petersen PH, Ricós C. Power function of the reference change value in relation to cut-off points, reference intervals and index of individuality. Clin Chem Lab Med. 2005;43:441–8.

APA	Dikker O, SAHIN M (2019). Use of Reference Change Value for Dyslipidemia Follow up. , 63 - 69.
Chicago	Dikker Okan,SAHIN MUSTAFA Use of Reference Change Value for Dyslipidemia Follow up. (2019): 63 - 69.
MLA	Dikker Okan,SAHIN MUSTAFA Use of Reference Change Value for Dyslipidemia Follow up. , 2019, ss.63 - 69.
AMA	Dikker O,SAHIN M Use of Reference Change Value for Dyslipidemia Follow up. . 2019; 63 - 69.
Vancouver	Dikker O,SAHIN M Use of Reference Change Value for Dyslipidemia Follow up. . 2019; 63 - 69.
IEEE	Dikker O,SAHIN M "Use of Reference Change Value for Dyslipidemia Follow up." , ss.63 - 69, 2019.
ISNAD	Dikker, Okan - SAHIN, MUSTAFA. "Use of Reference Change Value for Dyslipidemia Follow up". (2019), 63-69.

APA	Dikker O, SAHIN M (2019). Use of Reference Change Value for Dyslipidemia Follow up. Türk Klinik Biyokimya Dergisi, 17(2), 63 - 69.
Chicago	Dikker Okan,SAHIN MUSTAFA Use of Reference Change Value for Dyslipidemia Follow up. Türk Klinik Biyokimya Dergisi 17, no.2 (2019): 63 - 69.
MLA	Dikker Okan,SAHIN MUSTAFA Use of Reference Change Value for Dyslipidemia Follow up. Türk Klinik Biyokimya Dergisi, vol.17, no.2, 2019, ss.63 - 69.
AMA	Dikker O,SAHIN M Use of Reference Change Value for Dyslipidemia Follow up. Türk Klinik Biyokimya Dergisi. 2019; 17(2): 63 - 69.
Vancouver	Dikker O,SAHIN M Use of Reference Change Value for Dyslipidemia Follow up. Türk Klinik Biyokimya Dergisi. 2019; 17(2): 63 - 69.
IEEE	Dikker O,SAHIN M "Use of Reference Change Value for Dyslipidemia Follow up." Türk Klinik Biyokimya Dergisi, 17, ss.63 - 69, 2019.
ISNAD	Dikker, Okan - SAHIN, MUSTAFA. "Use of Reference Change Value for Dyslipidemia Follow up". Türk Klinik Biyokimya Dergisi 17/2 (2019), 63-69.